Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats

Risa Nasu, Yoichi Kumagai, Hirokuni Kogetsu, Masayuki Tsujimoto, Hisakazu Ohtani, Yasufumi Sawada

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pralmorelin hydrochloride (pralmorelin), consisting of six amino acid residues, is a growth hormone-releasing peptide. The aim of this study is to analyze the pharmacokinetics of pralmorelin after intravenous bolus administration to rats, and to develop a physiologically based pharmacokinetic (PB-PK) model to describe and predict the concentrations of pralmorelin in blood and tissues. Pralmorelin (3 mg/kg) was administered intravenously to 24 Sprague-Dawley rats. Groups of three rats were sacrificed by decapitation at each designated time point (up to 4 h), and plasma and tissues (brain, lung, heart, liver, kidney, small intestine, muscle, adipose, and skin) were collected. Bile was also pooled until decapitation. The concentration of pralmorelin in samples was determined by liquid chromatography-tandem mass spectrometry. Plasma concentrations of pralmorelin declined rapidly in a biexponential manner. Biliary excretion of pralmorelin was so rapid that 80% of the dose was recovered unchanged in the bile within 1 h after administration. The distribution parameters in each tissue were obtained by using a hybrid model and an integration plot. They revealed that the distribution of pralmorelin into liver was blood flow-limited, and its distribution was permeability-limited in all other tissues. The PB-PK model developed in this study well described the time courses of pralmorelin concentration in the blood and tissues of rats.

Original languageEnglish
Pages (from-to)1488-1494
Number of pages7
JournalDrug Metabolism and Disposition
Volume33
Issue number10
DOIs
Publication statusPublished - 2005 Oct
Externally publishedYes

Fingerprint

Pharmacokinetics
Rats
Tissue
Decapitation
Blood
Bile
Liver
Plasmas
Liquid chromatography
Tandem Mass Spectrometry
Liquid Chromatography
Intravenous Administration
Small Intestine
Mass spectrometry
Sprague Dawley Rats
Muscle
Permeability
Brain
Skin
Kidney

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats. / Nasu, Risa; Kumagai, Yoichi; Kogetsu, Hirokuni; Tsujimoto, Masayuki; Ohtani, Hisakazu; Sawada, Yasufumi.

In: Drug Metabolism and Disposition, Vol. 33, No. 10, 10.2005, p. 1488-1494.

Research output: Contribution to journalArticle

Nasu, Risa ; Kumagai, Yoichi ; Kogetsu, Hirokuni ; Tsujimoto, Masayuki ; Ohtani, Hisakazu ; Sawada, Yasufumi. / Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats. In: Drug Metabolism and Disposition. 2005 ; Vol. 33, No. 10. pp. 1488-1494.
@article{ea63950e75704c6495974d9134d4b1e7,
title = "Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats",
abstract = "Pralmorelin hydrochloride (pralmorelin), consisting of six amino acid residues, is a growth hormone-releasing peptide. The aim of this study is to analyze the pharmacokinetics of pralmorelin after intravenous bolus administration to rats, and to develop a physiologically based pharmacokinetic (PB-PK) model to describe and predict the concentrations of pralmorelin in blood and tissues. Pralmorelin (3 mg/kg) was administered intravenously to 24 Sprague-Dawley rats. Groups of three rats were sacrificed by decapitation at each designated time point (up to 4 h), and plasma and tissues (brain, lung, heart, liver, kidney, small intestine, muscle, adipose, and skin) were collected. Bile was also pooled until decapitation. The concentration of pralmorelin in samples was determined by liquid chromatography-tandem mass spectrometry. Plasma concentrations of pralmorelin declined rapidly in a biexponential manner. Biliary excretion of pralmorelin was so rapid that 80{\%} of the dose was recovered unchanged in the bile within 1 h after administration. The distribution parameters in each tissue were obtained by using a hybrid model and an integration plot. They revealed that the distribution of pralmorelin into liver was blood flow-limited, and its distribution was permeability-limited in all other tissues. The PB-PK model developed in this study well described the time courses of pralmorelin concentration in the blood and tissues of rats.",
author = "Risa Nasu and Yoichi Kumagai and Hirokuni Kogetsu and Masayuki Tsujimoto and Hisakazu Ohtani and Yasufumi Sawada",
year = "2005",
month = "10",
doi = "10.1124/dmd.104.001040",
language = "English",
volume = "33",
pages = "1488--1494",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "10",

}

TY - JOUR

T1 - Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats

AU - Nasu, Risa

AU - Kumagai, Yoichi

AU - Kogetsu, Hirokuni

AU - Tsujimoto, Masayuki

AU - Ohtani, Hisakazu

AU - Sawada, Yasufumi

PY - 2005/10

Y1 - 2005/10

N2 - Pralmorelin hydrochloride (pralmorelin), consisting of six amino acid residues, is a growth hormone-releasing peptide. The aim of this study is to analyze the pharmacokinetics of pralmorelin after intravenous bolus administration to rats, and to develop a physiologically based pharmacokinetic (PB-PK) model to describe and predict the concentrations of pralmorelin in blood and tissues. Pralmorelin (3 mg/kg) was administered intravenously to 24 Sprague-Dawley rats. Groups of three rats were sacrificed by decapitation at each designated time point (up to 4 h), and plasma and tissues (brain, lung, heart, liver, kidney, small intestine, muscle, adipose, and skin) were collected. Bile was also pooled until decapitation. The concentration of pralmorelin in samples was determined by liquid chromatography-tandem mass spectrometry. Plasma concentrations of pralmorelin declined rapidly in a biexponential manner. Biliary excretion of pralmorelin was so rapid that 80% of the dose was recovered unchanged in the bile within 1 h after administration. The distribution parameters in each tissue were obtained by using a hybrid model and an integration plot. They revealed that the distribution of pralmorelin into liver was blood flow-limited, and its distribution was permeability-limited in all other tissues. The PB-PK model developed in this study well described the time courses of pralmorelin concentration in the blood and tissues of rats.

AB - Pralmorelin hydrochloride (pralmorelin), consisting of six amino acid residues, is a growth hormone-releasing peptide. The aim of this study is to analyze the pharmacokinetics of pralmorelin after intravenous bolus administration to rats, and to develop a physiologically based pharmacokinetic (PB-PK) model to describe and predict the concentrations of pralmorelin in blood and tissues. Pralmorelin (3 mg/kg) was administered intravenously to 24 Sprague-Dawley rats. Groups of three rats were sacrificed by decapitation at each designated time point (up to 4 h), and plasma and tissues (brain, lung, heart, liver, kidney, small intestine, muscle, adipose, and skin) were collected. Bile was also pooled until decapitation. The concentration of pralmorelin in samples was determined by liquid chromatography-tandem mass spectrometry. Plasma concentrations of pralmorelin declined rapidly in a biexponential manner. Biliary excretion of pralmorelin was so rapid that 80% of the dose was recovered unchanged in the bile within 1 h after administration. The distribution parameters in each tissue were obtained by using a hybrid model and an integration plot. They revealed that the distribution of pralmorelin into liver was blood flow-limited, and its distribution was permeability-limited in all other tissues. The PB-PK model developed in this study well described the time courses of pralmorelin concentration in the blood and tissues of rats.

UR - http://www.scopus.com/inward/record.url?scp=24944483111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944483111&partnerID=8YFLogxK

U2 - 10.1124/dmd.104.001040

DO - 10.1124/dmd.104.001040

M3 - Article

C2 - 16033952

AN - SCOPUS:24944483111

VL - 33

SP - 1488

EP - 1494

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 10

ER -